Physician

Jamal Gerges Maatouk, MD

According to 2025 Medicare claims, Jamal Maatouk, MD (NPI: 1205016060) practices medical oncology in the Johnson City, TN market, with the plurality of this provider's patient population coming from Washington, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37604-2011. Maatouk is affiliated with the AnewCare Collaborative, LLC (ACO ID: A1241), participating under the MSSP model.

Maatouk's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 260 traditional Medicare patients, billed 6,189 HCPCS/CPT codes, and received $176,195 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 641 prescription claims across 186 beneficiaries totaling $651,199 in drug costs, led by Xarelto (Rivaroxaban). 2016 DME data shows 30 claims. Open Payments data shows 15 records totaling $282. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $59,477 to $176,195. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $808,000 and ending at $651,199. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	282	852	$59,477
2016	321	8,325	$204,462
2017	413	80,207	$1,096,238
2018	595	129,294	$1,940,960
2019	512	22,683	$400,597
2020	443	1,303	$87,675
2021	405	1,093	$94,929
2022	374	760	$60,321
2023	313	620	$43,994
2024	260	6,189	$176,195

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	508	$808,000
2016	120	683	$1,744,756
2017	125	706	$1,736,165
2018	120	418	$549,749
2019	144	532	$998,261
2020	157	480	$491,294
2021	167	566	$480,868
2022	198	605	$736,469
2023	192	705	$1,827,127
2024	186	641	$651,199

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	25	$2,483
2016	N/R	30	$2,231
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	151	237	$73
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	105	122	$46
80053	Blood test, comprehensive group of blood chemicals	40	65	$10
36415	Insertion of needle into vein for collection of blood sample	44	71	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	45	75	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	19	630	$11,145
Exemestane	Exemestane	13	915	$3,097
Tamoxifen Citrate	Tamoxifen Citrate	52	4,350	$2,376
Anastrozole	Anastrozole	102	8,690	$2,186
Potassium Chloride	Potassium Chloride	36	1,434	$700

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$282	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jamal Gerges Maatouk, MD?

Tedicare shows public-source Medicare data for Jamal Gerges Maatouk, MD (NPI 1205016060), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jamal Gerges Maatouk, MD have ACO affiliation data?

Jamal Gerges Maatouk, MD is shown with ACO affiliation data for AnewCare Collaborative, LLC (MSSP, ACO ID A1241).

What billing organization is linked to Jamal Gerges Maatouk, MD?

Jamal Gerges Maatouk, MD is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Jamal Gerges Maatouk, MD have Open Payments data?

Jamal Gerges Maatouk, MD has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.